NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NewsGuard 100/100 Score

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

"The goal of the Smilow Center team is to help each patient make an informed decision about their treatment options for prostate cancer and choose the treatment that is the best fit for them personally and medically," said Herbert Lepor, MD, the Martin Spatz Chairman and Professor of Urology and director of The Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center. "Our Center's unique multi-disciplinary, collaborative and evidence-based approach will empower patients with information they need to make the best treatment decisions, thereby helping to ensure satisfaction with treatment outcomes."

Physicians and surgeons at the Smilow Center are among the most experienced physicians in the world. A multidisciplinary team of urologists, surgeons, naturopathic doctors, radiation oncologists and nurses work closely with patients to identify and select the optimal course of treatment for them, including active surveillance, surgery, radiation therapy and cryotherapy. Chemotherapy and immunotherapy are also available at The Cancer Institute at NYU Langone Medical Center.

Eligible patients at the Smilow Center also have the opportunity to participate in the latest clinical trials for prostate cancer, including minimally invasive focal targeted therapies, such as high-intensity focused ultrasound (HIFU) which uses high-energy sound waves to kill cancer cells and vascular-targeted photodynamic therapy utilizing light-energy waves to destroy prostate cancer.

The Smilow Center has also transformed the typical waiting room experience into an educational opportunity. When they arrive, patients are given iPads to access information on the Center's new educational website and interactive video library. Flat-screen televisions feature videos about prostate cancer and the latest treatments for the disease.

The Smilow Center is specially equipped with two operating rooms for out-patient procedures along with the technology needed for radiologists to facilitate image-guided ablative treatments which are being pioneered by the Smilow team. It is also an investigational site for the most advanced computer guided biopsy and imaging technology. The Center will also serve as an educational training facility for physicians, surgeons and fellows interested in learning about the diagnosis and treatment of prostate cancer, and includes video-broadcast telemedicine capabilities.

The Smilow Comprehensive Prostate Cancer Center is located at 135 East 31st Street between 3rd and Lexington Avenue in New York, NY. It is an integral component of the NCI-designated NYU Cancer Institute at NYU Langone Medical Center and the Department of Urology at NYU Langone Medical Center.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer